Clover Health Investments Statistics
Total Valuation
CLOV has a market cap or net worth of $1.29 billion. The enterprise value is $1.10 billion.
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLOV has 516.68 million shares outstanding. The number of shares has increased by 3.78% in one year.
| Current Share Class | 424.30M |
| Shares Outstanding | 516.68M |
| Shares Change (YoY) | +3.78% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 21.35% |
| Owned by Institutions (%) | 26.26% |
| Float | 404.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.71 |
| Forward PS | 0.51 |
| PB Ratio | 3.76 |
| P/TBV Ratio | 3.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.71
| Current Ratio | 1.71 |
| Quick Ratio | 1.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.90% and return on invested capital (ROIC) is -10.49%.
| Return on Equity (ROE) | -16.90% |
| Return on Assets (ROA) | -5.94% |
| Return on Invested Capital (ROIC) | -10.49% |
| Return on Capital Employed (ROCE) | -15.74% |
| Revenue Per Employee | $3.11M |
| Profits Per Employee | -$102,318 |
| Employee Count | 570 |
| Asset Turnover | 2.93 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.19% in the last 52 weeks. The beta is 2.23, so CLOV's price volatility has been higher than the market average.
| Beta (5Y) | 2.23 |
| 52-Week Price Change | -27.19% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 3.15 |
| Relative Strength Index (RSI) | 43.40 |
| Average Volume (20 Days) | 7,788,292 |
Short Selling Information
The latest short interest is 43.48 million, so 8.41% of the outstanding shares have been sold short.
| Short Interest | 43.48M |
| Short Previous Month | 43.09M |
| Short % of Shares Out | 8.41% |
| Short % of Float | 10.75% |
| Short Ratio (days to cover) | 4.01 |
Income Statement
In the last 12 months, CLOV had revenue of $1.77 billion and -$58.32 million in losses. Loss per share was -$0.12.
| Revenue | 1.77B |
| Gross Profit | 375.61M |
| Operating Income | -57.66M |
| Pretax Income | -57.71M |
| Net Income | -58.32M |
| EBITDA | -56.05M |
| EBIT | -57.66M |
| Loss Per Share | -$0.12 |
Full Income StatementBalance Sheet
The company has $202.84 million in cash and n/a in debt, giving a net cash position of $190.06 million or $0.37 per share.
| Cash & Cash Equivalents | 202.84M |
| Total Debt | n/a |
| Net Cash | 190.06M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 340.93M |
| Book Value Per Share | 0.66 |
| Working Capital | 137.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.62 million and capital expenditures -$1.76 million, giving a free cash flow of -$86.38 million.
| Operating Cash Flow | -84.62M |
| Capital Expenditures | -1.76M |
| Free Cash Flow | -86.38M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
Gross margin is 21.18%, with operating and profit margins of -3.25% and -3.29%.
| Gross Margin | 21.18% |
| Operating Margin | -3.25% |
| Pretax Margin | -3.25% |
| Profit Margin | -3.29% |
| EBITDA Margin | -3.16% |
| EBIT Margin | -3.25% |
| FCF Margin | n/a |
Dividends & Yields
CLOV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.78% |
| Shareholder Yield | -3.78% |
| Earnings Yield | -4.53% |
| FCF Yield | -6.71% |
Dividend DetailsAnalyst Forecast
The average price target for CLOV is $4.23, which is 69.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.23 |
| Price Target Difference | 69.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 22.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
